A 4-month chronic treatment with SAR255952 (10 mg/kg) significantly decreased guanidine-solubilized pan-Aβ levels (−41% at 10 mg/kg, p < 0.01) versus Ctl-IgG1-treated controls in the cortex while a nonsignificant trend was observed at 3 mg/kg (−25%) and no effect at 1 mg/kg (+6%) (Table 3 ).
← all excerpts
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
1
—
—